The New Biopharmaceutical Blueprint: Service-Oriented Architecture in Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The New Biopharmaceutical Blueprint: Service-Oriented Architecture in Manufacturing
More than ever, drug makers need to be fleet and flexible—and they need their software to be the same.


Pharmaceutical Technology


The collaborative nature of SOA can help address a new level of partnering and global reach that is necessary to stay competitive in the BioPharma industry both for today and the future. The authors expect that BioPharma leaders will make SOA a critical part of their organizational strategies to help them reach out to other organizations and bring the intended benefits to society on a global scale.

Pieter Deurinck* is a managing consultant and worldwide solutions architect for the Life Sciences/Pharmaceuticals team at IBM, Generaal Lemanstraat 69, 2018 Antwerp, Belgium,
Jay DiMare is an associate partner at IBM Global Business Services. Michael Ricci is a global relationship partner at IBM Global Business Services. Kathleen Martin is a managing consultant for the Life Sciences–Pharma-ceuticals team at the IBM Institute for Business Value.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here